Trial · NCT02598960
Results by group363
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 363
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part A: BMS-986156 10mg | Adverse Events (AEs) | 4 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part A: BMS-986156 30mg | Adverse Events (AEs) | 6 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part A: BMS-986156 100mg | Adverse Events (AEs) | 4 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part A: BMS-986156 240mg | Adverse Events (AEs) | 6 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part A: BMS-986156 800mg | Adverse Events (AEs) | 9 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part C: BMS-986156 240mg | Adverse Events (AEs) | 3 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part C: BMS-986156 800mg | Adverse Events (AEs) | 2 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part B: BMS-986156 30mg + Nivo 240mg | Adverse Events (AEs) | 3 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part B: BMS-986156 100mg + Nivo 240mg | Adverse Events (AEs) | 9 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part B: BMS-986156 240mg + Nivo 240mg | Adverse Events (AEs) | 14 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part B: BMS-986156 800mg + Nivo 240mg | Adverse Events (AEs) | 11 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part D: BMS-986156 240mg + Nivo 240mg | Adverse Events (AEs) | 188 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part E: BMS-986156 480mg + Nivo 480mg | Adverse Events (AEs) | 33 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part A: BMS-986156 10mg | Serious Adverse Events (SAEs) | 3 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part A: BMS-986156 30mg | Serious Adverse Events (SAEs) | 3 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part A: BMS-986156 100mg | Serious Adverse Events (SAEs) | 1 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part A: BMS-986156 240mg | Serious Adverse Events (SAEs) | 5 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part A: BMS-986156 800mg | Serious Adverse Events (SAEs) | 4 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part C: BMS-986156 240mg | Serious Adverse Events (SAEs) | 2 | Participants | |
| Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths | Part C: BMS-986156 800mg | Serious Adverse Events (SAEs) | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02598960/results